You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 28, 2024

CLINICAL TRIALS PROFILE FOR ENTRECTINIB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ENTRECTINIB

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02097810 ↗ Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Completed Hoffmann-La Roche Phase 1 2014-07-28 Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
NCT02097810 ↗ Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Completed Ignyta, Inc. Phase 1 2014-07-28 Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
NCT02568267 ↗ Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting Hoffmann-La Roche Phase 2 2015-11-19 This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
NCT02568267 ↗ Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting Ignyta, Inc. Phase 2 2015-11-19 This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
NCT02587650 ↗ Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated Adil Daud Phase 2 2015-03-26 This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02587650 ↗ Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated University of California, San Francisco Phase 2 2015-03-26 This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02650401 ↗ Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Recruiting Hoffmann-La Roche Phase 1/Phase 2 2016-05-03 This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ENTRECTINIB

Condition Name

Condition Name for ENTRECTINIB
Intervention Trials
Non-small Cell Lung Cancer 4
Solid Tumor 4
Melanoma 3
Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ENTRECTINIB
Intervention Trials
Neoplasms 10
Carcinoma, Non-Small-Cell Lung 6
Lung Neoplasms 4
Carcinoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ENTRECTINIB

Trials by Country

Trials by Country for ENTRECTINIB
Location Trials
United States 240
Italy 39
Spain 22
Australia 19
Brazil 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ENTRECTINIB
Location Trials
Oregon 12
Texas 11
California 11
Florida 10
Tennessee 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ENTRECTINIB

Clinical Trial Phase

Clinical Trial Phase for ENTRECTINIB
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 3
Phase 2 15
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ENTRECTINIB
Clinical Trial Phase Trials
Recruiting 19
Completed 6
Not yet recruiting 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ENTRECTINIB

Sponsor Name

Sponsor Name for ENTRECTINIB
Sponsor Trials
Hoffmann-La Roche 13
Genentech, Inc. 10
Ignyta, Inc. 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ENTRECTINIB
Sponsor Trials
Industry 52
Other 52
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.